|
Basis of Presentation (Details Textual) (USD $)
|
3 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2013
segment
|
Mar. 31, 2012
|
Dec. 31, 2012
|
Mar. 31, 2013
Equipment [Member]
Minimum [Member]
|
Mar. 31, 2013
Equipment [Member]
Maximum [Member]
|
Mar. 31, 2013
Cydex Pharmaceuticals, Inc [Member]
|
Dec. 31, 2012
Cydex Pharmaceuticals, Inc [Member]
|
Jan. 24, 2011
Cydex Pharmaceuticals, Inc [Member]
|
Jan. 31, 2012
Cydex Pharmaceuticals, Inc [Member]
Guaranteed Payment [Member]
|
Jan. 31, 2012
Cydex Pharmaceuticals, Inc [Member]
Revenue Sharing [Member]
|
Mar. 31, 2013
Cydex Pharmaceuticals, Inc [Member]
Revenue Sharing [Member]
|
Jan. 31, 2010
Metabasis Therapeutics [Member]
right
|
Mar. 31, 2013
Metabasis Therapeutics [Member]
|
Mar. 31, 2013
Neurogen Corporation [Member]
|
Dec. 31, 2009
Neurogen Corporation [Member]
right
|
Mar. 31, 2013
Neurogen Corporation [Member]
Contingent Value Rights VR1 [Member]
|
Mar. 31, 2013
Accounts Receivable [Member]
Customer Concentration Risk [Member]
customer
|
Dec. 31, 2012
Accounts Receivable [Member]
Customer Concentration Risk [Member]
customer
|
Mar. 31, 2013
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Major Customer 1 [Member]
|
Dec. 31, 2012
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Major Customer 1 [Member]
|
Mar. 31, 2013
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Major Customer 2 [Member]
|
Dec. 31, 2012
Accounts Receivable [Member]
Customer Concentration Risk [Member]
Major Customer 2 [Member]
|
|
| Basis of Presentation (Textual) [Abstract] | ||||||||||||||||||||||
| Accumulated deficit | $ (681,263,000) | $ (682,759,000) | ||||||||||||||||||||
| Working capital | (15,300,000) | |||||||||||||||||||||
| Period for which available resources are sufficient to satisfy company's anticipated operating and capital requirements | 12 months | |||||||||||||||||||||
| Potential common shares included in the computation of diluted income per share | 90,652 | 29,723 | ||||||||||||||||||||
| Common shares excluded from computation | 1,200,000 | 1,500,000 | ||||||||||||||||||||
| Maturity period of cash and cash equivalents, maximum | 3 months | |||||||||||||||||||||
| Maturity period of short term investments, minimum | 3 months | |||||||||||||||||||||
| FDIC insured amount | 250,000 | |||||||||||||||||||||
| Cash deposits | 4,400,000 | 11,900,000 | ||||||||||||||||||||
| Concentration risk, number of customers | 2 | 2 | ||||||||||||||||||||
| Concentration risk, percentage of accounts receivable | 64.00% | 53.00% | 28.00% | 35.00% | ||||||||||||||||||
| Estimated useful life of assets | 3 years | 10 years | ||||||||||||||||||||
| Depreciation | 100,000 | 100,000 | ||||||||||||||||||||
| Finite-lived intangible asset, useful life | 20 years | |||||||||||||||||||||
| Amortization expense | 600,000 | 600,000 | ||||||||||||||||||||
| Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] | ||||||||||||||||||||||
| Amortization Expense 2013 | 2,400,000 | |||||||||||||||||||||
| Amortization Expense 2014 | 2,400,000 | |||||||||||||||||||||
| Amortization Expense 2015 | 2,400,000 | |||||||||||||||||||||
| Amortization Expense 2016 | 2,400,000 | |||||||||||||||||||||
| Amortization Expense 2017 | 2,400,000 | |||||||||||||||||||||
| Contingent liability | 17,600,000 | |||||||||||||||||||||
| Paid to CyDex shareholders | 4,300,000 | 200,000 | 0 | |||||||||||||||||||
| Contingent liability fair value | 12,700,000 | 10,900,000 | ||||||||||||||||||||
| Contingent liability change in amount | 1,800,000 | (600,000) | (1,100,000) | (500,000) | (200,000) | |||||||||||||||||
| Number of contingent value rights | 4 | 4 | ||||||||||||||||||||
| Number of contingent value rights per series of contingent value rights | 1 | |||||||||||||||||||||
| Number of contingent value rights issued for each share | 4 | |||||||||||||||||||||
| Contingent value rights, frequency of cash payment | 6 months | |||||||||||||||||||||
| Period allowed for return of products, minimum | 30 days | |||||||||||||||||||||
| Period allowed for return of products, maximum | 90 days | |||||||||||||||||||||
| Accounts receivable outstanding considered past due after period, minimum | 30 days | |||||||||||||||||||||
| Accounts receivable outstanding considered past due after period, maximum | 90 days | |||||||||||||||||||||
| Allowance for doubtful accounts | 0 | 0 | ||||||||||||||||||||
| Deferred revenue | 600,000 | 800,000 | ||||||||||||||||||||
| Amount included in current portion of deferred revenue | 600,000 | |||||||||||||||||||||
| Amount included in long-term portion of deferred revenue | $ 40,000 | |||||||||||||||||||||
| Number of reportable segments | 2 | |||||||||||||||||||||